Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Mycosis Fungoides × cemiplimab × Clear all

Phase

Phase 1 2 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 6 Melanoma 6 Carcinoma, Non-Small-Cell Lung 6 Prostatic Neoplasms 4 Ovarian Neoplasms 4 Neoplasm Metastasis 4 Recurrence 3 Carcinoma, Renal Cell 3 Squamous Cell Carcinoma of Head and Neck 2 Pancreatic Neoplasms 2 Head and Neck Neoplasms 2 Fallopian Tube Neoplasms 2 Endometrial Neoplasms 2 Colorectal Neoplasms 2 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Solid Tumor 1 Skin Neoplasms 1 Mycosis Fungoides 1 Multiple Myeloma 1 Metastatic Castration-resistant Prostate Cancer 1 Lymphoma 1 Lung Neoplasms 1 Liposarcoma 1 Leiomyosarcoma 1 Hereditary Sensory and Autonomic Neuropathies 1 Glioma 1 Glioblastoma 1 Diffuse Intrinsic Pontine Glioma 1

Interventions

fludarabine phosphate 5 Peripheral Blood Stem Cell Transplantation 4 Immunoglobulin G 3 Everolimus 3 Disulfides 3 Cyclosporine 3 pembrolizumab 2 mogamulizumab 2 fludarabine 2 Whole-Body Irradiation 2 Tacrolimus 2 Photopheresis 2 Mycophenolic Acid 2 Methotrexate 2 Lenalidomide 2 Gene Expression Profiling 2 Etoposide 2 Cyclophosphamide 2 Busulfan 2 Bortezomib 2 romidepsin 1 navitoclax 1 magrolimab 1 liposomal doxorubicin 1 indolepropanol phosphate 1 flt3 ligand protein 1 ethanolamine oleate 1 durvalumab 1 cemiplimab 1 carmustine, poliferprosan 20 drug combination 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05538988 2025-06-27

BIOSELECT

AHS Cancer Control Alberta

Phase 1/2 Withdrawn

Mycosis Fungoides

Data powered by HemOnc (CC BY 4.0) Colophon ⚡